DRG Epidemiology's coverage of renal cell carcinoma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of renal cell carcinoma for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan, and they are forecast for 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, the number of drug-treatment opportunities at specific lines of therapy are forecast across the world.
DRG Epidemiology's renal cell carcinoma forecast will answer the following questions:
- How will changes in the level of exposure to known risk or protective factors affect the number of people diagnosed with renal cell carcinoma per year?
- Of all people diagnosed with renal cell carcinoma, how many in each country across the major mature pharmaceutical markets are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of renal cell carcinoma over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graphical depiction of the patient flow between or within different disease states for the major mature pharmaceutical markets. These patient flow diagrams are provided at the regional level but may be requested for any specific country or forecast year.
In total, DRG Epidemiology forecasts 27 renal cell carcinoma patient populations, as follows:
- Diagnosed incident cases.
- Diagnosed stage I-IV incident cases.
- Diagnosed metastatic recurrent incident cases.
- Diagnosed prevalent cases.
- Diagnosed early-stage (stages I-III) drug-treated population.
- Diagnosed first-line metastatic drug-treatable population.
- Diagnosed first-line metastatic drug-treated population.
- Diagnosed second-line metastatic drug-treatable population.
- Diagnosed second-line metastatic drug-treated population.
- Diagnosed third-line metastatic drug-treatable population.
- Diagnosed third-line metastatic drug-treated population.
- Diagnosed fourth-line metastatic drug-treatable population.
- Diagnosed fourth-line metastatic drug-treated population.
- … and many more (details available on request).
Note: Coverage may vary by country.
- Renal Cell Carcinoma - Epidemiology - Emerging Markets
- Key Findings
- Key Updates
- Diagnosed Incidence of Renal Cell Carcinoma per 100,000 People of All Ages per Year in 2021 and 2031
- Patient Flow Diagram for Renal Cell Carcinoma Across All Countries Under Study in 2021
- Relative Sizes of the Contributing Factors to the Trend in Diagnosed Incident Cases of Renal Cell Carcinoma Over the Next Ten Years
- Analysis of the Diagnosed Incident Cases of Renal Cell Carcinoma in 2021 by Stage Distribution
- Number of Additional Diagnosed Incident Cases of Renal Cell Carcinoma Incurred Over the Period 2021-2031 in the Countries Under Study Due to Trends in Risk
- Key Findings
- Epidemiology Data
- Diagnosed Incident Cases
- Stage Distribution of Renal Cell Carcinoma
- Histology Subtype
- Recurrent Incident Cases of Renal Cell Carcinoma
- Diagnosed Prevalent Cases
- Drug-Treatable Populations
- Drug-Treated Populations
- Lifetime DALYs Gained
- Reference Materials
- Literature Review
- Studies Included in the Analysis of Renal Cell Carcinoma
- Studies Excluded from the Analysis of Renal Cell Carcinoma
- Risk/Protective Factors
- Risk/Protective Factors for Renal Cell Carcinoma
- Literature Review
Author(s): Harinder Kumar; Alexandre Vo Dupuy, Pharm.D., M.Sc.
Harinder Kumar, B.D.S., M.P.H., is an associate epidemiologist at Clarivate. Previously, Dr. Kumar worked with the government of Punjab, National Health Mission, India. He received his M.P.H. from the Tata Institute of Social Sciences in Mumbai. He holds a B.D.S. in dentistry from the National Dental College and Hospital in Punjab.
Alexandre Vo Dupuy, M.Sc., Pharm.D., is a principal epidemiologist at Clarivate. Previously, he worked in the fields of consulting and real-world evidence and at a major pharmaceutical company. He obtained his doctor of pharmacy from Descartes University in Paris and his master’s degree in pharmacoepidemiology from the University of Bordeaux.